Skip to Content for Rienk Offringa Menu for Rienk Offringa About Us Menu Research Menu Development Menu Medicines Menu Investors Menu Media Menu Careers Menu
Banner Image

Rienk Offringa

Rienk Offringa
Rienk Offringa Principal Scientist: Immunology

Mentor Profile | Top Scientific Papers

Top Scientific Papers

  • van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A 2007 Jul 17; 104(29): 12087-92. View Abstract on PubMed

  • van Hall T, Wolpert EZ, van Veelen P, Laban S, van der Veer M, Roseboom M, Bres S, Grufman P, de Ru A, Meiring H, de Jong A, Franken K, Teixeira A, Valentijn R, Drijfhout JW, Koning F, Camps M, Ossendorp F, Kärre K, Ljunggren HG, Melief CJ, Offringa R. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 2006 Apr; 12(4): 417-24.

  • Bos R, van Duikeren S, van Hall T, Kaaijk P, Taubert R, Kyewski B, Klein L, Melief CJ, Offringa R. Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res 2005 Jul 15; 65(14): 6443-9. View Abstract on PubMed

  • Diehl L, van Mierlo GJ, den Boer AT, van der Voort E, Fransen M, van Bostelen L, Krimpenfort P, Melief CJ, Mittler R, Toes RE, Offringa R. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J Immunol 2002 Apr 15; 168(8): 3755-62. View Abstract on PubMed

  • de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002 Jan 15; 62(2): 472-9. View Abstract on PubMed

  • Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 2001 Sep 25; 98(20): 11515-20. View Abstract on PubMed

  • Medema JP, Schuurhuis DH, Rea D, van Tongeren J, de Jong J, Bres SA, Laban S, Toes RE, Toebes M, Schumacher TN, Bladergroen BA, Ossendorp F, Kummer JA, Melief CJ, Offringa R. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 2001 Sep 3; 194(5): 657-67. View Abstract on PubMed

  • Sutmuller RP, Schurmans LR, van Duivenvoorde LM, Tine JA, van Der Voort EI, Toes RE, Melief CJ, Jager MJ, Offringa R. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. J Immunol 2000 Dec 15; 165(12): 7308-15. View Abstract on PubMed

  • Rea D, van Kooten C, van Meijgaarden KE, Ottenhoff TH, Melief CJ, Offringa R. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 2000 May 15; 95(10): 3162-7. View Abstract on PubMed

  • Rea D, Schagen FH, Hoeben RC, Mehtali M, Havenga MJ, Toes RE, Melief CJ, Offringa R. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 1999 Dec; 73(12): 10245-53. View Abstract on PubMed

  • Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999 Oct 4; 190(7): 1033-8. View Abstract on PubMed

  • Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999 Jul; 5(7): 774-9. View Abstract on PubMed

  • van der Burg SH, Kwappenberg KM, Geluk A, van der Kruk M, Pontesilli O, Hovenkamp E, Franken KL, van Meijgaarden KE, Drijfhout JW, Ottenhoff TH, Melief CJ, Offringa R. Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. J Immunol 1999 Jan 1; 162(1): 152-60. View Abstract on PubMed

  • Schoenberger SP, Jonges LE, Mooijaart RJ, Hartgers F, Toes RE, Kast WM, Melief CJ, Offringa R. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res 1998 Jul 15; 58(14): 3094-100. View Abstract on PubMed

  • Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998 Jun 4; 393(6684): 480-3. View Abstract on PubMed

  • Toes RE, Hoeben RC, van der Voort EI, Ressing ME, van der Eb AJ, Melief CJ, Offringa R. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci U S A 1997 Dec 23; 94(26): 14660-5. View Abstract on PubMed

  • Offringa R, Bierer BE. Association of CD2 with tubulin. Evidence for a role of the cytoskeleton in T cell activation. J Biol Chem 1993 Mar 5; 268(7): 4979-88. View Abstract on PubMed

  • Offringa R, Gebel S, van Dam H, Timmers M, Smits A, Zwart R, Stein B, Bos JL, van der Eb A, Herrlich P. A novel function of the transforming domain of E1a: repression of AP-1 activity. Cell 1990 Aug 10; 62(3): 527-38. View Abstract on PubMed

  • Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, van der Eb AJ, Melief CJ. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 1989 Nov 17; 59(4): 603-14. View Abstract on PubMed